APA (7th ed.) Citation

Mohamed F. Zaky, Taha M. Hammady, Shadeed Gad, Abdullah Alattar, Reem Alshaman, Ann Hegazy, . . . Mohamed A. Megahed. (2023). Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban. MDPI AG.

Chicago Style (17th ed.) Citation

Mohamed F. Zaky, Taha M. Hammady, Shadeed Gad, Abdullah Alattar, Reem Alshaman, Ann Hegazy, Sawsan A. Zaitone, Mamdouh Mostafa Ghorab, and Mohamed A. Megahed. Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban. MDPI AG, 2023.

MLA (9th ed.) Citation

Mohamed F. Zaky, et al. Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban. MDPI AG, 2023.